Advertisement

THE CUTTING EDGE

This Slimy Little Sucker Could Save Your Life

Health: 'Eau de leech' has already proved itself as a blood clot buster. Now several firms are out to prove it can be economical as well.

September 21, 1998|PAUL JACOBS | TIMES STAFF WRITER

The leech, used for centuries to treat a variety of human ills and then abandoned with the rise of modern medicine, may be on the verge of new respectability thanks to recent breakthroughs in genetic engineering.

The slimy little bloodsuckers experienced a brief resurgence of medical interest several years ago, but they have been mostly relegated to the scummy ponds and swamps from which they came.

Now chemicals derived from leech saliva could finally provide their redemption. The substances, called hirudins, can be thought of as the chemical essence of leech. Their purpose is to stop blood from clotting while the 3-inch-long animals sip their suppers.

The chemicals have proved potent in preventing life-threatening blood clots in patients following hip replacement surgery, during heart attacks and in angioplasty, a procedure used to pry open the small arteries that nourish the heart.

A recently released international study showed that a leech-derived chemical could significantly reduce deaths and heart attacks in patients hospitalized with coronary artery disease.

The same hirudin, one brewed in baker's yeast modified by genetic engineering, won federal approval for patients who develop life-threatening complications following the use of one of the most popular anti-clotting agents. A Boston area company is about to test a synthetic version of the drug, called Hirulog, on 17,000 heart attack patients around the world.

There is general agreement that the hirudins are extraordinary drugs, superior in several ways to some of the most commonly prescribed alternatives. But the companies that invested in them have suffered several costly disappointments on the way to market. Several have given up the chase and sold off their rights.

The issue is not whether the leech chemicals work--they clearly do--but whether they offer enough of an advantage over other, cheaper medications to justify the added expense.

"If we lived in a magical world and we didn't have to consider cost, we'd immediately start prescribing Hirulog or hirudin," said Dr. Elliott Antman, director of the coronary care unit at Harvard's Brigham and Women's Hospital. Compared with heparin, one of the most widely used clot-preventing drugs, hirudin is more reliable and requires fewer blood tests, Antman said. "But we don't live in that magical world, and, as you know, budgetary issues now play a more frequent role in our discussions of medicines."

But as science continues to test new approaches to cleaning out clogged arteries and veins, several companies are now betting on the leech--hoping that they have found ways to use hirudins in combination with other drugs to save health-care dollars as well as patients' lives.

The number of individuals who could be affected are huge. More than 1 million Americans suffer from heart attacks each year and more than 430,000 undergo angioplasty, the American Heart Assn. estimates. For most of these patients, the use of drugs to prevent blood clot formation is now routine--with sales for some of the newer products exceeding $200 million a year.

Scientists searching for improved treatments for heart disease have learned important lessons from the European medicinal leech, Hirudo medicinalis, one of more than 600 species that swim the fresh waters of the world, feeding on the blood of other animals.

Historians trace its use back 2,500 years in India, China, Greece and Rome. But the leech reached its medicinal peak in the 19th century, when it "was considered a cure for nearly everything, including headache, fever, insomnia, ulcers and obesity," writes Roy T. Sawyer, who has devoted much of his career to reviving the commercial use of the leech.

The rise of modern medicine questioned all forms of bloodletting, and by the 20th century, leeches had fallen out of therapeutic favor.

But thanks to Sawyer and others, leeches gradually won back a small role in medical treatment. For more than 20 years, some reconstructive surgeons have been using them to break up clots and remove congested blood in reattached body parts--especially fingers, ears and scalps.

And at least two companies--Leeches USA and Sawyer's own Biopharm Leeches--supply the animals to hospitals throughout the country. Combined, the companies report selling 40,000 leeches a year at about $7 per animal.

It might take as many as 50 leeches applied over several weeks to save a reattached finger, hundreds of leeches to help restore a large flap of skin.

Although the animals bore in with their three-jawed mouths--each jaw lined with 100 tiny teeth--the procedure is remarkably pain-free. That's probably because the animals first inject an anesthetic, said Leeches USA Vice President Rudy Rosenberg Sr.

It's the chemicals in their saliva that have attracted the most intense medical interest.

Advertisement
Los Angeles Times Articles
|
|
|